Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs.

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M., Jean El-Cheikh, MD PhD, Stéphane Morisset, Stat., Anne Sirvent, MD, Oumedaly Reman, MD, Jérôme Cornillon, MD, Reza Tabrizi, MD, Noel Milpied, MD, Jean-Luc Harousseau, MD, Hélène Labussière-Wallet, MD, Franck E. Nicolini, MD, PhD, Charles Dumontet, M. D., Ph.D., Mohamad Mohty, Michel Attal, MD, Didier Blaise, MD, Philippe Moreau, MD, Hervé Avet-Loiseau, MD, PhD

Blood (2012) 120 (21): 3116.

https://doi.org/10.1182/blood.V120.21.3116.3116

Published: 2012

Journal Articles

Genome-Wide Aberrant Splicing in Patients with Acute Myelold Leukemia (AML) Is Associated with Altered Expression of Splicing Factors

Sophia Adamia, PhD, Hervé Avet-Loiseau, MD, PhD, Jana Jakubikova, Suzan Lazo-Kallanian, John Daley, PhD, Laurence Lode, Ph.D, Ilene Galinsky, ANP, Richard M. Stone, MD, James D. Griffin, MD

Blood (2012) 120 (21): 652.

https://doi.org/10.1182/blood.V120.21.652.652

Published: 2012

Journal Articles

Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies

Blood (2012) 120 (21): 749.

https://doi.org/10.1182/blood.V120.21.749.749

Published: 2012

Journal Articles

Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.

Blood (2012) 120 (21): 2932.

https://doi.org/10.1182/blood.V120.21.2932.2932

Published: 2012

Journal Articles

Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Indetifies Potential Novel Targets

Sophia Adamia, Ph.D, Michal Bar-Natan, M.D, Benjamin Haibe-Kains, Ph.D, Hervé Avet-Loiseau, MD, PhD, Laurence Lode, Ph.D, Samuel Pevzner, Sigitas Verselis, PhD, Edward Fox, PhD, Ilene Galinsky, ANP, John Quackenbush, Ph.D, Richard M. Stone, MD, James D Griffin, MD

Blood (2011) 118 (21): 761.

https://doi.org/10.1182/blood.V118.21.761.761

Published: 2011

Journal Articles

Are Gene Expression Signatures Treatment Specific?

Parantu K Shah, PhD, Stephane Minvielle, PhD, Hervé Avet-Loiseau, MD, PhD, Cheng Li, PhD, Nikhil C. Munshi, MD

Blood (2011) 118 (21): 807.

https://doi.org/10.1182/blood.V118.21.807.807

Published: 2011

Journal Articles

High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02

Blood (2011) 118 (21): 812.

https://doi.org/10.1182/blood.V118.21.812.812

Published: 2011

Journal Articles

Whole Genome Sequencing Defines the Clonal Architecture and Genomic Evolution in Myeloma: Tumor Heterogeneity with Continued Acquisition of New Mutational Change

Nikhil C. Munshi, MD, Hervé Avet-Loiseau, MD, PhD, Philip J. Stephens, Graham R Bignell, Yu-Tzu Tai, PhD, Masood Shammas, Ph.D, Cheng Li, PhD, Parantu K Shah, PhD, Mariateresa Fulciniti, PhD, Jagannath Pal, PhD, Ankit V Vahia, Ph.D, Paul G. Richardson, MD, Stephane Minvielle, PhD, Peter Campbell, Kenneth C. Anderson, MD, Andrew Futreal

Blood (2011) 118 (21): 297.

https://doi.org/10.1182/blood.V118.21.297.297

Published: 2011

Journal Articles

Incidence and Prognostic Value of Chromosomal Abnormalities in Elderly Patients with myeloma: The IFM Experience on 1095 Patients

Blood (2011) 118 (21): 994.

https://doi.org/10.1182/blood.V118.21.994.994

Published: 2011

Journal Articles

Alternate Splicing Factor Fox2 Affects Growth and Survival of Multiple Myeloma Cells

Weihua Song, MD, Yiguo Hu, PhD, Guang Yang, PhD, Parantu K Shah, PhD, Weisong Shan, MD PhD, Yu-Tzu Tai, PhD, Yi Li, PhD, Stephane Minvielle, PhD, Hervé Avet-Loiseau, MD, PhD, Kenneth C. Anderson, MD, Cheng Li, PhD, Nikhil C. Munshi, MD

Blood (2011) 118 (21): 1810.

https://doi.org/10.1182/blood.V118.21.1810.1810

Published: 2011

Journal Articles

Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program

Murielle Roussel, Nelly Robillard, Philippe Moreau, MD, Lotfi Benboubker, MD, PhD, Cyrille Hulin, MD, Gerald Marit, MD, PhD, Xavier Leleu, MD, PhD, Brigitte Pegourie, MD, Christophe Fruchart, MD, Denis Caillot, MD, Anne-Marie Stoppa, MD, Thierry Facon, MD, Soraya Wuilleme, MD, PhD, Hervé Avet-Loiseau, MD, PhD, Michel Attal, MD

Blood (2011) 118 (21): 1872.

https://doi.org/10.1182/blood.V118.21.1872.1872

Published: 2011

Journal Articles

Evaluation of the Intra-LABORATORY Reproducibility of Percentage of Blast Counting In MYELODYSPLASIA

Soraya Wuilleme, MD, PhD, Marion Eveillard, Sophie Barillet, Françoise Accard, Hervé Avet-Loiseau, MD, PhD, Jacques Delaunay, MD, Richard Garand

Blood (2011) 118 (21): 4901.

https://doi.org/10.1182/blood.V118.21.4901.4901

Published: 2011

Journal Articles

Gene Expression Profile Alone Is Inadequate In Predicting Complete Responses In Multiple Myeloma

Samir B. Amin, MBBS, Stephane Minvielle, PhD, Bret Hanlon, PhD, Parantu K Shah, PhD, Cheng Li, PhD, Yi Li, PhD, David Swanson, PhD, Philippe Moreau, MD, Florence Magrangeas, PhD, Kenneth C. Anderson, MD, Hervé Avet-Loiseau, MD, PhD, Nikhil C. Munshi, MD

Blood (2010) 116 (21): 306.

https://doi.org/10.1182/blood.V116.21.306.306

Published: 2010

Journal Articles

High Resolution Genome-Wide Analyses Revealed That Bortezomib Selects a Prediagnosis Clone In Relapsed Patients with Multiple Myeloma

Florence Magrangeas, Hervé Avet-Loiseau, Olivier Decaux, Wilfried Gouraud, jean Luc Harousseau, Kenneth C. Anderson, Philippe Moreau, MD, Nikhil C. Munshi, MD, Stephane Minvielle

Blood (2010) 116 (21): 2960.

https://doi.org/10.1182/blood.V116.21.2960.2960

Published: 2010

Journal Articles

Long-Term Maintenance with Lenalidomide Improves Progression Free Survival In Myeloma Patients with High-Risk Cytogenetics: An IFM Study

Blood (2010) 116 (21): 1944.

https://doi.org/10.1182/blood.V116.21.1944.1944

Published: 2010

Journal Articles

Elevated Homologous Recombination Induces Karyotypic Changes and Predicts Poor Clinical Outcome In Multiple Myeloma

Jagannath Pal, Jeffrey Sawyer, Samir B. Amin, MBBS, Cheng Li, Puru Nanjappa, Saem Lee, B.A., Stephane Minvielle, Hervé Avet-Loiseau, Masood Shammas, Nikhil C. Munshi

Blood (2010) 116 (21): 1924.

https://doi.org/10.1182/blood.V116.21.1924.1924

Published: 2010

Journal Articles

An Integrative Analysis of Network Motifs and Gene Expression Data to Discover Experimentally Testable Transcription Factor-miRNA-Gene Regulatory Loops In Multiple Myeloma

Samir B. Amin, MBBS, Zhenyu Yan, PhD, Parantu Shah, PhD, Jesús F. San Miguel, Sr, MD, PhD, Stephane Minvielle, PhD, Hervé Avet-Loiseau, MD, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD, Cheng Li, PhD

Blood (2010) 116 (21): 1926.

https://doi.org/10.1182/blood.V116.21.1926.1926

Published: 2010

Journal Articles

A Combined Survival Model Integrating Gene Expression and Alternative Splicing Events Provides Higher Predicative Power for Risk Stratification

Parantu K Shah, PhD, Hervé Avet-Loiseau, Stephane Minvielle, Samir B. Amin, MBBS, Florence Magrangeas, Kenneth C. Anderson, Cheng Li, PhD, Nikhil C. Munshi, MD

Blood (2010) 116 (21): 1929.

https://doi.org/10.1182/blood.V116.21.1929.1929

Published: 2010

Journal Articles

Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02

Blood (2010) 116 (21): 859.

https://doi.org/10.1182/blood.V116.21.859.859

Published: 2010

Journal Articles

High Bcl-2/Mcl-1 Gene Expression Ratio Identifies Molecular Sub-Groups of Multiple Myeloma Patients Extremely Sensitive to ABT-737

Linda Bodet, Catherine Pellat-Deceunynck, PhD, Patricia Gomez-Bougie, PhD, Christelle Dousset, Cyrille Touzeau, Steven Le Gouill, MD, PhD, Hervé Avet-Loiseau, MD, PhD, Regis Bataille, MD, PhD, Martine Amiot, PhD

Blood (2010) 116 (21): 4061.

https://doi.org/10.1182/blood.V116.21.4061.4061

Published: 2010

NARROW

Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs.

Genome-Wide Aberrant Splicing in Patients with Acute Myelold Leukemia (AML) Is Associated with Altered Expression of Splicing Factors

Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies

Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.

Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Indetifies Potential Novel Targets

Are Gene Expression Signatures Treatment Specific?

High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02

Whole Genome Sequencing Defines the Clonal Architecture and Genomic Evolution in Myeloma: Tumor Heterogeneity with Continued Acquisition of New Mutational Change

Incidence and Prognostic Value of Chromosomal Abnormalities in Elderly Patients with myeloma: The IFM Experience on 1095 Patients

Alternate Splicing Factor Fox2 Affects Growth and Survival of Multiple Myeloma Cells

Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program

Evaluation of the Intra-LABORATORY Reproducibility of Percentage of Blast Counting In MYELODYSPLASIA

Gene Expression Profile Alone Is Inadequate In Predicting Complete Responses In Multiple Myeloma

High Resolution Genome-Wide Analyses Revealed That Bortezomib Selects a Prediagnosis Clone In Relapsed Patients with Multiple Myeloma

Long-Term Maintenance with Lenalidomide Improves Progression Free Survival In Myeloma Patients with High-Risk Cytogenetics: An IFM Study

Elevated Homologous Recombination Induces Karyotypic Changes and Predicts Poor Clinical Outcome In Multiple Myeloma

An Integrative Analysis of Network Motifs and Gene Expression Data to Discover Experimentally Testable Transcription Factor-miRNA-Gene Regulatory Loops In Multiple Myeloma

A Combined Survival Model Integrating Gene Expression and Alternative Splicing Events Provides Higher Predicative Power for Risk Stratification

Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02

High Bcl-2/Mcl-1 Gene Expression Ratio Identifies Molecular Sub-Groups of Multiple Myeloma Patients Extremely Sensitive to ABT-737

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only